{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:43:05Z","timestamp":1781890985171,"version":"3.54.5"},"reference-count":72,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck &amp; Co., Inc.","award":["T90-DE02198213"],"award-info":[{"award-number":["T90-DE02198213"]}]},{"name":"the National Institute of Dental and Craniofacial Research","award":["T90-DE02198213"],"award-info":[{"award-number":["T90-DE02198213"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Mycobacterium abscessus (MABS) is an opportunistic pathogen that causes chronic, difficult-to-treat pulmonary infections, particularly in people with cystic fibrosis (PwCF), leading to rapid lung function decline and increased morbidity and mortality. Treatment is particularly challenging due to the pathogen\u2019s resistance mechanisms and the need for prolonged multidrug therapy, which is characterized by poor clinical outcomes and highlights the urgent need for novel therapeutic strategies. Imipenem\/relebactam, a novel \u03b2-lactam-\u03b2-lactamase inhibitor combination, demonstrates in vitro activity against resistant MABS strains and effective pulmonary penetration. Prior research indicates synergistic activity of imipenem with various antibiotics against M. abscessus. Objectives: This study aims to evaluate the in vitro activity of imipenem\/relebactam, alone and in combination with various antibiotics, against MABS clinical isolates from PwCF (n = 28). Methods: Susceptibility and synergy were assessed using broth microdilution and checkerboard assays. Extracellular time-kill assays were performed to evaluate the bactericidal activity of synergistic three-drug combinations containing imipenem\/relebactam. Results: Imipenem\/relebactam demonstrated potent in vitro activity against clinical MABS isolates, exhibiting substantial synergy with cefuroxime, cefdinir, amoxicillin, and cefoxitin. Rifabutin, azithromycin, moxifloxacin, clofazimine, and minocycline also demonstrated additive effects with imipenem\/relebactam. Extracellular time-kill assays identified imipenem\/relebactam + cefoxitin + rifabutin and imipenem\/relebactam + cefoxitin + moxifloxacin as the most effective combinations. Conclusions: These findings suggest that imipenem\/relebactam may offer a significant advancement in the management of MABS infections in PwCF. The promising efficacy of multidrug regimens combining imipenem\/relebactam with agents like cefoxitin, azithromycin, moxifloxacin, clofazimine, and rifabutin highlights potential therapeutic strategies.<\/jats:p>","DOI":"10.3390\/antibiotics14050486","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T10:58:07Z","timestamp":1747047487000},"page":"486","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["In Vitro Activity of Imipenem\/Relebactam Alone and in Combination Against Cystic Fibrosis Isolates of Mycobacterium abscessus"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8386-0907","authenticated-orcid":false,"given":"Madeline","family":"Sanders","sequence":"first","affiliation":[{"name":"Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Woo","family":"Kim","sequence":"additional","affiliation":[{"name":"Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Shinde","sequence":"additional","affiliation":[{"name":"Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Fletcher-Williams","sequence":"additional","affiliation":[{"name":"Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Quach","sequence":"additional","affiliation":[{"name":"Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3744-3310","authenticated-orcid":false,"given":"Paul","family":"Beringer","sequence":"additional","affiliation":[{"name":"Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jcf.2013.12.003","article-title":"The relative frequency of CFTR mutation classes in European patients with cystic fibrosis","volume":"13","author":"Zolin","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1513\/AnnalsATS.201709-727OC","article-title":"Epidemiology of pulmonary nontuberculous mycobacterial sputum positivity in patients with cystic fibrosis in the United States, 2010\u20132014","volume":"15","author":"Adjemian","year":"2018","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_5","unstructured":"Cystic Fibrosis Foundation (2025, May 09). 2023 Patient Registry: Annual Data Report. Available online: https:\/\/www.cff.org\/media\/34491\/download."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Marshall, J.E., Mercaldo, R.A., Lipner, E.M., and Prevots, D.R. (2023). Incidence of nontuberculous mycobacteria infections among persons with cystic fibrosis in the United States (2010\u20132019). BMC Infect. Dis., 23.","DOI":"10.1186\/s12879-023-08468-6"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.celrep.2019.01.071","article-title":"CFTR Protects against Mycobacterium abscessus Infection by Fine-Tuning Host Oxidative Defenses","volume":"26","author":"Bernut","year":"2019","journal-title":"Cell Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e0081220","DOI":"10.1128\/IAI.00812-20","article-title":"Nontuberculous mycobacteria, macrophages, and host innate immune response","volume":"89","author":"Shamaei","year":"2021","journal-title":"Infect. Immun."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Tour\u00e9, H., Galindo, L.A., Lagune, M., Glatigny, S., Waterhouse, R.M., Gu\u00e9nal, I., Herrmann, J.L., Girard-Misguich, F., and Szuplewski, S. (2023). Mycobacterium abscessus resists the innate cellular response by surviving cell lysis of infected phagocytes. PLoS Pathog., 19.","DOI":"10.1371\/journal.ppat.1011257"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jcf.2012.06.009","article-title":"Mycobacterium avium and Mycobacterium abscessus complex target distinct cystic fibrosis patient subpopulations","volume":"12","author":"Catherinot","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jcf.2015.09.007","article-title":"Comparing the harmful effects of nontuberculous mycobacteria and Gram-negative bacteria on lung function in patients with cystic fibrosis","volume":"15","author":"Qvist","year":"2016","journal-title":"J. Cyst. Fibros."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_13","unstructured":"Barto, T.L., and Olivier, K.N. (2025, May 09). Nontuberculous mycobacteria clinical care guidelines. Available online: https:\/\/www.cff.org\/medical-professionals\/nontuberculous-mycobacteria-clinical-care-guidelines."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1801991","DOI":"10.1183\/13993003.01991-2018","article-title":"Mycobacterium abscessus pulmonary disease: Individual patient data meta-analysis","volume":"54","author":"Kwak","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Chen, J., Zhao, L., Mao, Y., Ye, M., Guo, Q., Zhang, Y., Xu, L., Zhang, Z., Li, B., and Chu, H. (2019). Clinical efficacy and adverse effects of antibiotics used to treat Mycobacterium abscessus pulmonary disease. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.01977"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/jac\/dkr578","article-title":"Mycobacterium abscessus: A new antibiotic nightmare","volume":"67","author":"Nessar","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Luthra, S., Rominski, A., and Sander, P. (2018). The role of antibiotic-target-modifying and antibiotic-modifying enzymes in Mycobacterium abscessus drug resistance. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.02179"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/jac\/dkt410","article-title":"Characterization of broad-spectrum Mycobacterium abscessus class A \u03b2-lactamase","volume":"69","author":"Soroka","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3201\/2109.141634","article-title":"Mycobacterium abscessus complex infections in humans","volume":"21","author":"Lee","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lopeman, R.C., Harrison, J., Rathbone, D.L., Desai, M., Lambert, P.A., and Cox, J.A.G. (2020). Effect of amoxicillin in combination with imipenem-relebactam against Mycobacterium abscessus. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-57844-8"},{"key":"ref_22","first-page":"379","article-title":"Impact of relebactam-mediated inhibition of Mycobacterium abscessus BlaMab \u03b2-lactamase on the in vitro and intracellular efficacy of imipenem","volume":"75","author":"Atze","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Yang, Q., Yang, Y., He, R., Yu, B., Zhong, Y., and Lin, F. (2023). Efficacy and safety of novel carbapenem-\u03b2-lactamase inhibitor combinations: Imipenem-cilastatin\/relebactam results from randomized controlled trials. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1304369"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e02623-18","DOI":"10.1128\/AAC.02623-18","article-title":"In vitro activity of the new \u03b2-lactamase inhibitors relebactam and vaborbactam in combination with \u03b2-lactams against Mycobacterium abscessus complex clinical isolates","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"106938","DOI":"10.1016\/j.ijantimicag.2023.106938","article-title":"In vitro susceptibility testing of imipenem-relebactam and tedizolid against 102 Mycobacterium abscessus isolates","volume":"62","author":"Burke","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/bcp.12901","article-title":"Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid","volume":"81","author":"Rizk","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e01411-17","DOI":"10.1128\/AAC.01411-17","article-title":"Intrapulmonary pharmacokinetics of relebactam, a novel \u03b2-lactamase inhibitor, dosed in combination with imipenem-cilastatin in healthy subjects","volume":"62","author":"Rizk","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijantimicag.2007.05.003","article-title":"In vitro efficacy of imipenem in combination with six antimicrobial agents against Mycobacterium abscessus","volume":"30","author":"Miyasaka","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Takei, S., Ihara, H., Togo, S., Nakamura, A., Fujimoto, Y., Watanabe, J., Kurokawa, K., Shibayama, K., Sumiyoshi, I., and Ochi, Y. (2020). The synergetic effect of imipenem-clarithromycin combination in the Mycobacteroides abscessus complex. BMC Microbiol., 20.","DOI":"10.1186\/s12866-020-02000-5"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e02613-18","DOI":"10.1128\/AAC.02613-18","article-title":"Select \u03b2-lactam combinations exhibit synergy against Mycobacterium abscessus in vitro","volume":"63","author":"Maggioncalda","year":"2019","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e02895-18","DOI":"10.1128\/mBio.02895-18","article-title":"Dual \u03b2-lactam combinations highly active against Mycobacterium abscessus complex in vitro","volume":"10","author":"Pandey","year":"2019","journal-title":"mBio"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e00084-24","DOI":"10.1128\/spectrum.00084-24","article-title":"In vitro effects of the new oral \u03b2-lactamase inhibitor xeruborbactam in combination with oral \u03b2-lactams against clinical Mycobacterium abscessus isolates","volume":"12","author":"Yamatani","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1128\/AAC.46.10.3164-3167.2002","article-title":"Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria","volume":"46","author":"Wallace","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1093\/jac\/dkae336","article-title":"Mycobacterium abscessus strain variability in preclinical drug development: Does it really matter?","volume":"79","author":"Mudde","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.2147\/IDR.S362583","article-title":"In vitro susceptibility of nontuberculous mycobacteria to tedizolid","volume":"15","author":"Zhang","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e00155-17","DOI":"10.1128\/AAC.00155-17","article-title":"Rifabutin is active against Mycobacterium abscessus complex","volume":"61","author":"Aziz","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e00718-23","DOI":"10.1128\/spectrum.00718-23","article-title":"Omadacycline, eravacycline, and tigecycline express anti-Mycobacterium abscessus activity in vitro","volume":"11","author":"Li","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e0234621","DOI":"10.1128\/aac.02346-21","article-title":"In vitro bedaquiline and clofazimine susceptibility testing in Mycobacterium abscessus","volume":"66","author":"Schulthess","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Woods, G.L., Brown-Elliott, B.A., Conville, P.S., Desmond, E.P., Hall, G.S., Lin, G., Pfyffer, G.E., Ridderhof, J.C., Siddiqi, S.H., and Wallace, R.J. (2011). Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes, Clinical and Laboratory Standards Institute. [2nd ed.]. Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK544374\/.","DOI":"10.1128\/9781555816728.ch73"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kreutzfeldt, K.M., McAdam, P.R., Claxton, P., Holmes, A., Seagar, A.L., Laurenson, I.F., and Fitzgerald, J.R. (2013). Molecular longitudinal tracking of Mycobacterium abscessus spp. during chronic infection of the human lung. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0063237"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Choo, S.W., Wee, W.Y., Ngeow, Y.F., Mitchell, W., Tan, J.L., Wong, G.J., Zhao, Y., and Xiao, J. (2014). Genomic reconnaissance of clinical isolates of emerging human pathogen Mycobacterium abscessus reveals high evolutionary potential. Sci. Rep., 4.","DOI":"10.1038\/srep04061"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"eabb8699","DOI":"10.1126\/science.abb8699","article-title":"Stepwise pathogenic evolution of Mycobacterium abscessus","volume":"372","author":"Bryant","year":"2021","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1080\/21505594.2021.1959808","article-title":"Genetic diversification of persistent Mycobacterium abscessus within cystic fibrosis patients","volume":"12","author":"Lewin","year":"2021","journal-title":"Virulence"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2215602","DOI":"10.1080\/21505594.2023.2215602","article-title":"Evolution of Mycobacterium abscessus in the human lung: Cumulative mutations and genomic rearrangement of porin genes in patient isolates","volume":"14","author":"Shallom","year":"2023","journal-title":"Virulence"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e00614-19","DOI":"10.1128\/AAC.00614-19","article-title":"Synergistic efficacy of \u03b2-lactam combinations against Mycobacterium abscessus pulmonary infection in mice","volume":"63","author":"Maggioncalda","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e0009023","DOI":"10.1128\/aac.00090-23","article-title":"Novel synergies and isolate specificities in the drug interaction landscape of Mycobacterium abscessus","volume":"67","author":"Van","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1128\/AAC.40.7.1617","article-title":"Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects","volume":"40","author":"Conte","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/jac\/37.2.331","article-title":"Distribution of cefdinir, a third generation cephalosporin antibiotic, in serum and pulmonary compartments","volume":"37","author":"Cook","year":"1996","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1136\/thx.49.11.1134","article-title":"Concentration of amoxycillin and clavulanate in lung compartments in adults without pulmonary infection","volume":"49","author":"Cook","year":"1994","journal-title":"Thorax"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2165\/00003088-198815060-00001","article-title":"Clinical pharmacokinetics of doxycycline and minocycline","volume":"15","author":"Saivin","year":"1988","journal-title":"Clin. Pharmacokinet."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/infdis\/jit614","article-title":"In vivo evaluation of antibiotic activity against Mycobacterium abscessus","volume":"209","author":"Lerat","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2016.05.025","article-title":"Long-term effects of azithromycin in patients with cystic fibrosis","volume":"117","author":"Samson","year":"2016","journal-title":"Respir. Med."},{"key":"ref_53","first-page":"CD002203","article-title":"Macrolide antibiotics (including azithromycin) for cystic fibrosis","volume":"2024","author":"Southern","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"L343","DOI":"10.1152\/ajplung.00030.2006","article-title":"Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1\/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line","volume":"292","author":"Blau","year":"2007","journal-title":"Am. J. Physiol. -Lung Cell. Mol. Physiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e02052-16","DOI":"10.1128\/AAC.02052-16","article-title":"Clofazimine-containing regimen for the treatment of Mycobacterium abscessus lung disease","volume":"61","author":"Yang","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"ofz456","DOI":"10.1093\/ofid\/ofz456","article-title":"Clinical outcomes of clofazimine use for rapidly growing mycobacteria infections","volume":"6","author":"Carey","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Dick, T. (2020). Rifabutin: A repurposing candidate for Mycobacterium abscessus lung disease. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.00371"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e00363-20","DOI":"10.1128\/AAC.00363-20","article-title":"Rifabutin is bactericidal against intracellular and extracellular forms of Mycobacterium abscessus","volume":"64","author":"Johansen","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Aziz, D.B., Go, M.L., and Dick, T. (2020). Rifabutin suppresses inducible clarithromycin resistance in Mycobacterium abscessus by blocking induction of whiB7 and erm41. Antibiotics, 9.","DOI":"10.3390\/antibiotics9020072"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1128\/AAC.01275-08","article-title":"A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae","volume":"53","author":"Nash","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e0139923","DOI":"10.1128\/aac.01399-23","article-title":"Comprehensive stability analysis of 13 \u03b2-lactams and \u03b2-lactamase inhibitors in in vitro media, and novel supplement dosing strategy to mitigate thermal drug degradation","volume":"68","author":"Zhou","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1055\/s-0033-1333575","article-title":"Management of nontuberculous mycobacterial (NTM) lung disease","volume":"34","author":"Philley","year":"2013","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1128\/AAC.02282-15","article-title":"Amikacin pharmacokinetics\/pharmacodynamics in a novel hollow-fiber Mycobacterium abscessus disease model","volume":"60","author":"Ferro","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Maggioncalda, E.C., Story-Roller, E., Mylius, J., Illei, P., Basaraba, R.J., and Lamichhane, G. (2020). A mouse model of pulmonary Mycobacteroides abscessus infection. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-60452-1"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Riva, C., Tortoli, E., Cugnata, F., Sanvito, F., Esposito, A., Rossi, M., Colarieti, A., Canu, T., Cigana, C., and Bragonzi, A. (2020). A new model of chronic Mycobacterium abscessus lung infection in immunocompetent mice. Int. J. Mol. Sci., 21.","DOI":"10.1101\/2020.07.30.228247"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1513\/AnnalsATS.202009-1214OC","article-title":"Population genomics of Mycobacterium abscessus from U.S. cystic fibrosis care centers","volume":"18","author":"Davidson","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0031-6997(25)00026-2","article-title":"What is synergy?","volume":"41","author":"Berenbaum","year":"1989","journal-title":"Pharmacol. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"O1124","DOI":"10.1111\/1469-0691.12780","article-title":"In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex","volume":"20","author":"Singh","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1128\/AAC.02615-15","article-title":"Clofazimine prevents the regrowth of Mycobacterium abscessus and Mycobacterium avium type strains exposed to amikacin and clarithromycin","volume":"60","author":"Ferro","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1345\/aph.19074","article-title":"A time-kill evaluation of clarithromycin and azithromycin against two extracellular pathogens and the development of resistance","volume":"33","author":"Burgess","year":"1999","journal-title":"Ann. Pharmacother."},{"key":"ref_71","unstructured":"Barry, A.L., Craig, W.A., Nadler, H., Reller, L.B., Sanders, C.C., and Swenson, J.M. (1999). Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline (NCCLS Document M26-A), Clinical and Laboratory Standards Institute."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1128\/AAC.00257-08","article-title":"Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus","volume":"52","author":"Leonard","year":"2008","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/5\/486\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:30:29Z","timestamp":1760031029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/5\/486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":72,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["antibiotics14050486"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14050486","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.12.10.627836","asserted-by":"object"}]},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]}}}